Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Системный медикаментозный тромболизис в лечении пациентов с ишемическим инсультом
Системный медикаментозный тромболизис в лечении пациентов с ишемическим инсультом
М.А.Домашенко, М.Ю.Максимова, М.А.Лоскутников, М.В.Глебов, А.А.Никонов, Т.А.Болотова, З.А.Суслина. Системный медикаментозный тромболизис в лечении пациентов с ишемическим инсультом. Consilium Medicum. Неврология (Прил.). 2010; 2: 4-8.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М., 2001.
2. Суслина З.А., Пирадов М.А. Инсульт. Диагностика, лечение и профилактика. Руководство для врачей. М., 2008.
3. Суслина З.А. Очерки ангионеврологии. М., 2005.
4. Rha J-H, Saver JL. The Impact of Recanalization on Ischemic Stroke Outcome. A Meta-Analysis. Stroke 2007; 38: 967–73.
5. The Multicenter Acute Stroke Trial-Europe (MAST-E) Study Group. Thrombolytic therapy with Streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145–50.
6. The Multicentre Acute Stroke Trial-Italy (MAST-I) Study Group. Randomised controlled trial of Streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995; 346: 1509–14.
7. Donnan GA et al. for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996; 276: 961–6.
8. Hacke W et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–25.
9. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7.
10. Hacke W et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245–51.
11. Clark WM. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999; 282 (21): 2019–26.
12. Wardlaw JM et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; CD000213.
13. Hacke W et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 2004; 363: 768–74.
14. Hacke W et al. Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM 2008; 359 (13): 1317–29.
15. Lees KR et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 2010; 375: 1695–703.
16. Wahlgren N et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Trrombolysis in Stroke-Monitoring Study (SIST-MOST): an observational study. Lancet 2007; 369: 275–82.
17. Ahmed N et al. Implementation and outcome of thrombolysis with alteplase 3–4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology 2010; 9: 866–74.
18. Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008: http://www.eso-stroke.org/recommendations
19. Adams H et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007; 38: 1655–711.
20. Wardlaw C, Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke. BMJ 2003 (1); 326 (7383): 233–4.
21. Molina CA et al. Thrombolysis-related hemorrhagic infarction. A marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002; 33: 1551–6.
22. Lansberg MG et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007; 38: 2275–8.
23. Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему. Анналы клинич. и экспер. неврол. 2007; 1: 17–22.
24. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59 (6): 862–7.
2. Суслина З.А., Пирадов М.А. Инсульт. Диагностика, лечение и профилактика. Руководство для врачей. М., 2008.
3. Суслина З.А. Очерки ангионеврологии. М., 2005.
4. Rha J-H, Saver JL. The Impact of Recanalization on Ischemic Stroke Outcome. A Meta-Analysis. Stroke 2007; 38: 967–73.
5. The Multicenter Acute Stroke Trial-Europe (MAST-E) Study Group. Thrombolytic therapy with Streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145–50.
6. The Multicentre Acute Stroke Trial-Italy (MAST-I) Study Group. Randomised controlled trial of Streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995; 346: 1509–14.
7. Donnan GA et al. for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996; 276: 961–6.
8. Hacke W et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–25.
9. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7.
10. Hacke W et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245–51.
11. Clark WM. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999; 282 (21): 2019–26.
12. Wardlaw JM et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; CD000213.
13. Hacke W et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 2004; 363: 768–74.
14. Hacke W et al. Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM 2008; 359 (13): 1317–29.
15. Lees KR et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 2010; 375: 1695–703.
16. Wahlgren N et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Trrombolysis in Stroke-Monitoring Study (SIST-MOST): an observational study. Lancet 2007; 369: 275–82.
17. Ahmed N et al. Implementation and outcome of thrombolysis with alteplase 3–4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology 2010; 9: 866–74.
18. Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008: http://www.eso-stroke.org/recommendations
19. Adams H et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007; 38: 1655–711.
20. Wardlaw C, Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke. BMJ 2003 (1); 326 (7383): 233–4.
21. Molina CA et al. Thrombolysis-related hemorrhagic infarction. A marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002; 33: 1551–6.
22. Lansberg MG et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007; 38: 2275–8.
23. Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему. Анналы клинич. и экспер. неврол. 2007; 1: 17–22.
24. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59 (6): 862–7.
Авторы
М.А.Домашенко, М.Ю.Максимова, М.А.Лоскутников, М.В.Глебов, А.А.Никонов, Т.А.Болотова, З.А.Суслина
Научный центр неврологии РАМН, Москва
Научный центр неврологии РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.